本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

NLS Pharmaceutics Ltd.

2.44
-0.1300-5.06%
盘后2.490.0500+2.05%16:39 EDT
成交量:11.02万
成交额:26.99万
市值:1,197.55万
市盈率:-0.37
高:2.59
开:2.55
低:2.34
收:2.57
数据加载中...
2022/12/13

SEC问询函

CORRESP [Cover] - Correspondence
2022/06/17

SEC问询函

CORRESP [Cover] - Correspondence
2022/06/10

招股说明书

F-1 - Registration statement for certain foreign private issuers
2022/03/24

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/24

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/18

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/10

SEC问询函

CORRESP [Cover] - Correspondence
2022/01/11

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/04

SEC问询函

CORRESP [Cover] - Correspondence
2021/12/20

招股说明书

F-1 - Registration statement for certain foreign private issuers
2021/11/01

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/11/01

SEC问询函

CORRESP [Cover] - Correspondence
2021/10/22

招股说明书

F-1 - Registration statement for certain foreign private issuers
2021/10/08

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/05/14

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/17

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/04

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/01/25

SEC问询函

CORRESP [Cover] - Correspondence
2021/01/25

SEC问询函

CORRESP [Cover] - Correspondence